ArticleInternational journal of molecular sciences2017
Melatonin and Hippo Pathway: Is There Existing Cross-Talk?
Article in International journal of molecular sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 179 citations in OpenAlex.
- Melatonin receptor signaling in human pathologies: from molecular mechanisms to therapeutic targets.Function (Oxford, England) · 2026Review
- Effects of melatonin in polycystic ovary syndrome: is there Hippo pathway crosstalk?Journal of ovarian research · 2025Review
- Melatonin-based priming of stem cells to alleviate oxidative stress.World journal of stem cells · 2024Article
- Melatonin alleviates aging-related heart failure through melatonin receptor 1A/B knockout in mice.Heliyon · 2024Article
- Potential Therapeutic Approach of Melatonin against Omicron and Some Other Variants of SARS-CoV-2.Molecules (Basel, Switzerland) · 2022Review
- The rationale for treating uveal melanoma with adjuvant melatonin: a review of the literature.BMC cancer · 2022Review
- Can Antioxidants Reduce the Toxicity of Bisphenol?Antioxidants (Basel, Switzerland) · 2022Review
- Field cancerization profile-based prognosis signatures lead to more robust risk evaluation in hepatocellular carcinoma.iScience · 2022Article
- Therapeutic Effect of Melatonin in Premature Ovarian Insufficiency: Hippo Pathway Is Involved.Oxidative medicine and cellular longevity · 2022Review
- Melatonin signalling in Schwann cells during neuroregeneration.Frontiers in cell and developmental biology · 2022Review
- Melatonin as a Therapeutic Agent for the Inhibition of Hypoxia-Induced Tumor Progression: A Description of Possible Mechanisms Involved.International journal of molecular sciences · 2021Review
- Possible benefits of exogenous melatonin for individuals on dialysis: a narrative review on potential mechanisms and clinical implications.Naunyn-Schmiedeberg's archives of pharmacology · 2021Review
- Melatonin Downregulates PD-L1 Expression and Modulates Tumor Immunity in KRAS-Mutant Non-Small Cell Lung Cancer.International journal of molecular sciences · 2021Article
- Hippo signaling: bridging the gap between cancer and neurodegenerative disorders.Neural regeneration research · 2021Article
- Age Associated Decrease of MT-1 Melatonin Receptor in Human Dermal Skin Fibroblasts Impairs Protection Against UV-Induced DNA Damage.International journal of molecular sciences · 2020Article
- Melatonin Regulates Cisplatin Resistance and Glucose Metabolism Through Hippo Signaling in Hepatocellular Carcinoma Cells.Cancer management and research · 2020Article
- RNA-Seq transcriptome analysis shows anti-tumor actions of melatonin in a breast cancer xenograft model.Scientific reports · 2019Article
- Reduction of Mitophagy-Related Oxidative Stress and Preservation of Mitochondria Function Using Melatonin Therapy in an HT22 Hippocampal Neuronal Cell Model of Glutamate-Induced Excitotoxicity.Frontiers in endocrinology · 2019Article
- Functional annotation of extensively and divergently expressed miRNAs in suprachiasmatic nucleus ofBioscience reports · 2018Article
- Repurposing of Drugs Targeting YAP-TEAD Functions.Cancers · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Melatonin is an indolic hormone that regulates a plethora of functions ranging from the regulation of circadian rhythms and antioxidant properties to the induction and maintenance of tumor suppressor pathways. It binds to specific receptors as well as to some cytosolic proteins, leading to several cellular signaling cascades. Recently, the involvement of melatonin in cancer insurgence and progression has clearly been demonstrated. In this review, we will first describe the structure and functions of melatonin and its receptors, and then discuss both molecular and epidemiological evidence on melatonin anticancer effects. Finally, we will shed light on potential cross-talk between melatonin signaling and the Hippo signaling pathway, along with the possible implications for cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.